ARCHIVES

Kadcyla Extends Median PFS In Open-Label Phase III Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 10 | October 25, 2013

Download PDF Visit The Full Archive

Related Articles

Techniclone Wins Patent For Tumor Necrosis Therapy.

February 25, 2000

Daniel Hayes Elected President of ASCO

December 12, 2014

DRCA Board Okays Concepts For Five Contract Projects

June 25, 1981

Conversation with The Cancer Letter: Statistician Lori Dodd Saw Research Question In the Midst of 2007 ODAC Debate Over Avastin

July 27, 2012

Tobacco Linked To 63 Percent Of Cancer Deaths In Black Men

July 29, 2005

How Much Is Life Worth? The $440 Billion Question

July 31, 2009